These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
571 related articles for article (PubMed ID: 10343019)
1. Consumer-directed advertising of contraceptive drugs: the FDA, Depo-Provera, and product liability. Green W Food Drug Law J; 1995; 50(4):553-67. PubMed ID: 10343019 [No Abstract] [Full Text] [Related]
2. The FDA, contraceptive marketing approval and products liability litigation: Depo-Provera and the risk of osteoporosis. Green W Food Drug Law J; 2013; 68(2):115-35, i. PubMed ID: 24640465 [TBL] [Abstract][Full Text] [Related]
9. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval. O'Reilly JT Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397 [No Abstract] [Full Text] [Related]
11. Pharmaceutical industry wins "round one" in protections against product liability claims. Gatty B Hosp Formul; 1995 Apr; 30(4):238, 237. PubMed ID: 10141868 [No Abstract] [Full Text] [Related]
12. The Lohr decision: FDA perspective and position. Porter MJ Food Drug Law J; 1997; 52(1):7-11. PubMed ID: 10346705 [No Abstract] [Full Text] [Related]
13. Permitting product liability litigation for FDA-approved drugs and devices promotes patient safety. Kesselheim AS Clin Pharmacol Ther; 2010 Jun; 87(6):645-7. PubMed ID: 20485322 [TBL] [Abstract][Full Text] [Related]
14. To inform or persuade? Direct-to-consumer advertising of prescription drugs. Berndt ER N Engl J Med; 2005 Jan; 352(4):325-8. PubMed ID: 15673797 [No Abstract] [Full Text] [Related]
15. The case for preemption of prescription drug failure-to-warn claims. Kim CH Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969 [No Abstract] [Full Text] [Related]